News >

Nivolumab Spurs Responses in non-CRC Patients With dMMR

Anita T. Shaffer @Shaffer1
Published: Saturday, Nov 11, 2017

Dr Nilofer S. Azad
Nilofer S. Azad, M
Nivolumab (Opdivo) demonstrated a 24% overall response rate (ORR) among patients with a range of non-colorectal cancers (CRCs) with mismatch repair deficiency (dMMR) who were identified through the NCI-MATCH trial, according to preliminary clinical trial findings reported at the 32nd SITC Annual Meeting.

Overall, 8 of 34 patients achieved a response for a 24% ORR (95% CI, 11%-41%); all were deemed partial responses (PRs) although there were 2 unconfirmed complete responses. “We did meet our primary endpoint,” Azad said. “…Of note, we had 5 more patients who had unconfirmed responses. Two of those patients remained on study at the time of data cutoff, so these response numbers may change as the study matures.”

The disease control rate, which consists of PRs, CRs, and stable disease, was 56%. The benefit was seen across histologies. “The duration of benefit was compelling for these patients,” Azad said. “The median time to response was 2.1 cycles and the 6-month progression-free survival was 49% [95% CI, 32%-67%].”

She said the median duration of response had not been reached at the time of data cutoff and that 11 patients overall were still undergoing treatment.

In terms of adverse events (AEs), Azad said the safety profile of nivolumab was consistent with that seen in prior studies. Treatment-related AEs consisted mostly of low-grade AEs; common all-grade AEs included fatigue (15%), anemia (10%), hypothyroidism, (6%), and anorexia (6%).
Azad N, Overman M, Gray R, et al. Nivolumab in mismatch-repair deficient (MMR-d) cancers: NCI-MATCH Trial (Molecular Analysis for Therapy Choice) Arm Z1D preliminary results.: Presented at: 32nd SITC Annual Meeting; November 9-12, 2017; National Harbor, MD. Abstract O37.


... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication
External Resources

MJH Associates
American Journal of Managed Care
MD Magazine
Oncology Nursing News
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
OncLive Resources

Conference Coverage
OncLive TV
Peer Exchange
Web Exclusives

About Us
Advisory Board
Contact Us
Forgot Password
Press Releases
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-939-0221

Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.